Posted by Michael Wonder on 11 Nov 2020
Decision to widen access to treatments for juvenile idiopathic arthritis
11 November 2020 - PHARMAC is pleased to announce a decision to widen access to adalimumab and etanercept for the treatment of polyarticular course juvenile idiopathic arthritis (JIA) and oligoarticular course JIA from 1 December 2020.
PHARMAC is also widening access to tocilizumab for the treatment of polyarticular course JIA from 1 December 2020.
